My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Glaukos Corporation Common Stock (NY:GKOS)

116.64 -4.36 (-3.60%)

Streaming Delayed Price Updated: 11:05 AM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Glaukos (GKOS) Q4 2025 Earnings Call Transcript ↗

February 17, 2026

Glaukos (GKOS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Glaukos Corp (NYSE:GKOS) Reports Record 2025 Sales but Shares Dip on Wider Loss, Conservative Outlook ↗

February 17, 2026

Via Chartmill

Director Sells GKOS 15,000 Shares for $1.9 Million ↗

January 31, 2026

This ophthalmic device maker, focused on glaucoma solutions, reported a notable insider sale after a challenging year for its stock.

Via The Motley Fool

Topics Regulatory Compliance

These stocks are moving in today's after hours session ↗

January 13, 2026

Via Chartmill

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Expert Outlook: Glaukos Through The Eyes Of 4 Analysts ↗

September 22, 2025

Via Benzinga

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

Earnings Scheduled For April 30, 2025 ↗

April 30, 2025

Via Benzinga

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗

February 24, 2025

Via Benzinga

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off ↗

November 06, 2025

Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off

Via The Motley Fool

Topics Regulatory Compliance

Why Glaukos Stock Zoomed Almost 14% Higher on Thursday ↗

October 30, 2025

The company's recent past featured robust growth, and it anticipates continued rises into the near future.

Via The Motley Fool

Glaukos (GKOS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Glaukos (GKOS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗

October 30, 2025

Via Benzinga

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

October 30, 2025

The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 30, 2025

Via Benzinga

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 30, 2025

Via Benzinga

Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗

October 30, 2025

Via Benzinga

Why Glaukos Stock Jumped Over 20% After-Hours Today ↗

October 29, 2025

Glaukos shares surged 21% in after-hours trading after the company posted record third-quarter revenue and raised its full-year guidance.

Via Stocktwits

What's going on in today's after hours session ↗

October 29, 2025

The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Glaukos Corp (NYSE:GKOS) Soars on Strong Q3 2025 Earnings Beat and Robust 2026 Outlook ↗

October 29, 2025

Glaukos (GKOS) smashed Q3 2025 earnings forecasts, sending its stock soaring. The company posted record revenue and raised its 2025 and 2026 sales guidance.

Via Chartmill

Topics Earnings

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 29, 2025

Via Benzinga

Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday ↗

October 27, 2025

Via Benzinga

This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

October 27, 2025

Via Benzinga

Expert Outlook: Glaukos Through The Eyes Of 7 Analysts ↗

October 13, 2025

Via Benzinga

Glaukos (GKOS) Q2 Revenue Jumps 30% ↗

August 01, 2025

Via The Motley Fool

What 11 Analyst Ratings Have To Say About Glaukos ↗

May 02, 2025

Via Benzinga

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

May 01, 2025

Via Benzinga

Forecasting The Future: 7 Analyst Projections For Glaukos ↗

April 16, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years ↗

March 28, 2025

Via Benzinga

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery ↗

February 24, 2025

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.